These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 117574)

  • 1. [Dose distribution of bone-seeking radiopharmaceuticals in the rat (author's transl)].
    Schümichen C; Hermannsdörfer A; Wüst H; Hoffmann G
    Strahlentherapie; 1979 Nov; 155(11):796-801. PubMed ID: 117574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complexing of reduced technetium and tin(II) by chelating phosphate compounds. II. In vitro stability of pyrophosphate and ethane-1, hydroxy-1, diphosphonate (EHDP) complexes.
    Schümichen C; Hohloch M; Hoffmann G
    Nuklearmedizin; 1979 May; 18(2):105-9. PubMed ID: 38437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marrow toxicity of 33P-versus 32P-orthophosphate: implications for therapy of bone pain and bone metastases.
    Goddu SM; Bishayee A; Bouchet LG; Bolch WE; Rao DV; Howell RW
    J Nucl Med; 2000 May; 41(5):941-51. PubMed ID: 10809212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemistry of technetium radiopharmaceuticals. I. Exploration of the tissue distribution and oxidation state consequences of technetium (IV) in Tc-Sn-gluconate and Tc-Sn-EHDP using carrier 99Tc.
    Hambright P; McRae J; Valk PE; Bearden AJ; Shipley BA
    J Nucl Med; 1975 Jun; 16(6):478-82. PubMed ID: 808594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complexing of reduced technetium and tin (II) by chelating phosphate compounds. I. Chemical state of technetium.
    Schümichen C; Hohloch H; Schiller A; Pohle W; Hoffmann G
    Nuklearmedizin; 1979 May; 18(2):98-104. PubMed ID: 38438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marrow-sparing effects of 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer.
    Bishayee A; Rao DV; Srivastava SC; Bouchet LG; Bolch WE; Howell RW
    J Nucl Med; 2000 Dec; 41(12):2043-50. PubMed ID: 11138691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technetium-99m-methylene diphosphonate--a superior agent for skeletal imaging: comparison with other technetium complexes.
    Subramanian G; McAfee JG; Blair RJ; Kallfelz FA; Thomas FD
    J Nucl Med; 1975 Aug; 16(8):744-55. PubMed ID: 170385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technetium-99m-labeled stannous imidodiphosphate, a new radiodiagnostic agent for bone scanning: comparison with other 99mTc complexes.
    Subramanian G; McAfee JG; Blair RJ; Rosenstreich M; Coco M; Duxbury CE
    J Nucl Med; 1975 Dec; 16(12):1137-43. PubMed ID: 1194964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comparison of osteotropic radiopharmaceuticals. II. Plasma clearance of 18F and 99mTc-EHDP (author's transl)].
    Creutzig H
    Rofo; 1975 Oct; 123(4):313-8. PubMed ID: 129388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative investigations of osteotropic isotopes. i animal experiments on the uptake of 18f, 85sr and 99mtc-ehdp (author's transl)].
    Creutzig H; Creutzig A; Gerdts KG; Greif E; Eckhardt W
    Rofo; 1975 Aug; 123(2):137-43. PubMed ID: 129373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative animal experiments concerning the distribution of 99mTc-pyrophosphate, 99mTc-diphosphonate and 85Sr (author's transl)].
    Büll U; Balser D; Frey KW
    Fortschr Geb Rontgenstr Nuklearmed; 1974 Apr; 120(4):481-8. PubMed ID: 4367024
    [No Abstract]   [Full Text] [Related]  

  • 12. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
    Liepe K; Geidel HH; Bergmann R; Haase M; Runge R; Kotzerke J
    Nucl Med Commun; 2009 Sep; 30(9):693-9. PubMed ID: 19528873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The short-term fixation of radiopharmaceuticals in bone.
    Schümichen C; Rempfle H; Wagner M; Hoffmann G
    Eur J Nucl Med; 1979 Dec; 4(6):423-8. PubMed ID: 520356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabeled bone-seeking radiopharmaceuticals.
    Atkins HL; Srivastava SC
    Q J Nucl Med; 1996 Sep; 40(3):285-9. PubMed ID: 8961805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dependence of the relation of 113Sn/113mIn in bone in contrast to 47Ca and 85Sr].
    Grimm W; Kaufmann A; Kutzner J
    Strahlentherapie Sonderb; 1975; 74():314-20. PubMed ID: 1198659
    [No Abstract]   [Full Text] [Related]  

  • 17. Bone extraction and blood clearance of diphosphonate in the dog.
    Hughes SP; Davies DR; Bassingthwaighte JB; Knox FG; Kelly PJ
    Am J Physiol; 1977 Mar; 232(3):H341-7. PubMed ID: 402827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting uptake and retention of technetium-99m-diphosphonate and 99m-pertechnetate in osseous, connective and soft tissues.
    Francis MD; Slough CL; Tofe AJ
    Calcif Tissue Res; 1976 Jun; 20(3):303-11. PubMed ID: 182328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biokinetics of osteotropic radiopharmaceuticals in metabolic osteopathy--comparison of 47Ca and 99mTc-methylene-diphosphonate (MDP)].
    Knop J; Montz R
    Nuklearmedizin; 1983 Oct; 22(5):226-31. PubMed ID: 6228781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Technetium-99m-pyrophosphate: studies in vivo and in vitro.
    Kaye M; Silverton S; Rosenthall L
    J Nucl Med; 1975 Jan; 16(1):40-5. PubMed ID: 162947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.